Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A.
Epilepsia. 2014 Nov;55(11):1844-53. doi: 10.1111/epi.12790. Epub 2014 Sep 19.
Anterior temporal lobectomy is curative for many patients with disabling medically refractory temporal lobe epilepsy, but carries an inherent risk of disabling verbal memory loss. Although accurate prediction of iatrogenic memory loss is becoming increasingly possible, it remains unclear how much weight such predictions should have in surgical decision making. Here we aim to create a framework that facilitates a systematic and integrated assessment of the relative risks and benefits of surgery versus medical management for patients with left temporal lobe epilepsy.
We constructed a Markov decision model to evaluate the probabilistic outcomes and associated health utilities associated with choosing to undergo a left anterior temporal lobectomy versus continuing with medical management for patients with medically refractory left temporal lobe epilepsy. Three base-cases were considered, representing a spectrum of surgical candidates encountered in practice, with varying degrees of epilepsy-related disability and potential for decreased quality of life in response to post-surgical verbal memory deficits.
For patients with moderately severe seizures and moderate risk of verbal memory loss, medical management was the preferred decision, with increased quality-adjusted life expectancy. However, the preferred choice was sensitive to clinically meaningful changes in several parameters, including quality of life impact of verbal memory decline, quality of life with seizures, mortality rate with medical management, probability of remission following surgery, and probability of remission with medical management.
Our decision model suggests that for patients with left temporal lobe epilepsy, quantitative assessment of risk and benefit should guide recommendation of therapy. In particular, risk for and potential impact of verbal memory decline should be carefully weighed against the degree of disability conferred by continued seizures on a patient-by-patient basis.
对于许多患有药物难治性颞叶癫痫且致残的患者来说,前颞叶切除术是一种有效的治疗方法,但会带来言语记忆丧失的固有风险。尽管预测医源性记忆丧失的准确性越来越高,但仍不清楚这些预测在手术决策中应占多大比重。在这里,我们旨在建立一个框架,以便系统地综合评估手术与药物治疗对左侧颞叶癫痫患者的相对风险和益处。
我们构建了一个马尔可夫决策模型,以评估选择接受左侧前颞叶切除术与继续药物治疗对药物难治性左侧颞叶癫痫患者的概率结果和相关健康效用。考虑了三种基本情况,代表了实践中遇到的一系列手术候选者,他们具有不同程度的癫痫相关残疾和术后言语记忆缺陷对生活质量的潜在影响。
对于中度严重发作和言语记忆丧失风险中等的患者,药物治疗是首选决策,可提高质量调整生命预期。然而,首选决策对几个参数的临床意义变化很敏感,包括言语记忆下降对生活质量的影响、癫痫发作时的生活质量、药物治疗的死亡率、手术缓解的概率以及药物治疗的缓解概率。
我们的决策模型表明,对于左侧颞叶癫痫患者,风险和益处的定量评估应指导治疗建议。特别是,应根据言语记忆减退的风险和潜在影响,以及持续癫痫发作对患者的残疾程度,在患者个体基础上仔细权衡。